Home » Stocks » Abbott Laboratories

Abbott Laboratories (ABT)

Stock Price: $92.72 USD -0.96 (-1.02%)
Updated Jul 10, 2020 1:00 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 164.00B
Revenue (ttm) 32.10B
Net Income (ttm) 3.58B
Shares Out 1.77B
EPS (ttm) 1.99
PE Ratio 46.59
Forward PE 22.27
Dividend $1.44
Dividend Yield 1.55%

Stock Quote

Trading Day Jul 10, 2020
Last Price $92.72
Previous Close $93.67
Change ($) -0.96
Change (%) -1.02%
Day's Open 93.47
Day's Range 92.35 - 93.80
Day's Volume 1,226,732
52-Week Range 61.61 - 100.00

More Stats

Market Cap 164.00B
Enterprise Value 178.60B
Earnings Date (est) Jul 16, 2020
Ex-Dividend Date Apr 14, 2020
Shares Outstanding 1.77B
Float 1.76B
EPS (basic) 2.02
EPS (diluted) 1.99
FCF / Share 2.53
Dividend $1.44
Dividend Yield 1.55%
Earnings Yield 2.15%
FCF Yield 2.73%
Payout Ratio 65.30%
Shares Short 12.82M
Short Ratio 1.78
Short % of Float 0.74%
Beta 0.96
PE Ratio 46.59
Forward PE 22.27
P/FCF Ratio 36.64
PS Ratio 5.11
PB Ratio 5.40
Revenue 32.10B
Operating Income 4.55B
Net Income 3.58B
Free Cash Flow 4.48B
Net Cash -14.60B
Net Cash / Share -8.26
Gross Margin 58.29%
Operating Margin 14.18%
Profit Margin 11.20%
FCF Margin 13.95%
ROA 4.59%
ROE 11.56%
ROIC 14.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (21)

Buy 15
Overweight 1
Hold 3
Underweight 1
Sell 1

Analyst Consensus: Buy

Price Target

$101.94*
(9.95% upside)
Low
84.0
Current: 92.72
High
113.0
Target: 101.94
*Average 12-month price target from 16 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue31,90430,57827,39020,85320,40520,24719,65719,05021,40735,167
Revenue Growth4.34%11.64%31.35%2.2%0.78%3%3.19%-11.01%-39.13%-
Gross Profit18,67317,87214,98111,75911,65811,02910,46410,15111,39020,502
Operating Income4,5323,6501,5643,0262,8672,5992,1331,3601,6296,088
Net Income3,6872,3684771,4004,4232,2842,5765,9634,7284,626
Shares Outstanding1,7681,7581,7401,4771,4961,5161,5581,5751,5571,546
Earnings Per Share2.061.330.270.942.921.491.623.723.012.96
EPS Growth54.89%392.59%-71.28%-67.81%95.97%-8.02%-56.45%23.59%1.69%-
Dividend Per Share1.281.121.061.040.960.8835.212.011.881.72
Dividend Growth14.29%5.66%1.92%8.33%9.09%-97.5%1651.74%6.91%9.3%-
Operating Cash Flow6,1366,3005,5703,2032,9663,6753,3249,3148,9708,736
Capital Expenditures-1,638-1,394-1,135-1,121-1,110-1,077-1,145-1,795-1,491-1,015
Free Cash Flow4,4984,9064,4352,0821,8562,5982,1797,5197,4797,721
Cash & Equivalents4,1404,0869,61018,7756,1254,4608,09815,1748,0977,324
Total Debt18,13919,56627,92422,0069,0017,8306,56120,47615,41518,918
Net Cash / Debt-13,999-15,480-18,314-3,231-2,876-3,3701,537-5,302-7,317-11,594
Assets67,88767,17376,25052,66641,24741,20742,95367,23560,27760,574
Liabilities36,58636,45145,15231,94919,92119,56817,68640,42235,75137,809
Book Value31,30130,72231,09820,71721,32621,63925,26726,81324,52622,765
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Abbott Laboratories
Country United States
Employees 107,000
CEO Robert B. Ford

Stock Information

Ticker Symbol ABT
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Medical Devices
Unique Identifier NYSE: ABT

Description

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems for infectious diseases; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. Its Nutritional Products segment provides pediatric and adult nutritional products. The company's Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. This segment also provides glucose and blood glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.